Cited by 336RNA Research and SplicingDNA Repair MechanismsPARP inhibition in cancer therapy

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

CDK12 regulates DNA repair genes by suppressing intronic polyadenylation

Open access

Dubbury, Sara J., Boutz, Paul L., Sharp, Phillip A.·2018·Nature

DOI 10.1038/s41586-018-0758-yPMC PMC6328294

Open this paper in CoChat — free account Open PDF

Abstract

Mutations that attenuate homologous recombination (HR)-mediated repair promote tumorigenesis and sensitize cells to chemotherapeutics that cause replication fork collapse, a phenotype known as 'BRCAness'1. BRCAness tumours arise from loss-of-function mutations in 22 genes 1. Of these genes, all but one (CDK12) function directly in the HR repair pathway 1. CDK12 phosphorylates serine 2 of the RNA polymerase II C-terminal domain heptapeptide repeat 2-7, a modification that regulates transcription elongation, splicing, and cleavage and polyadenylation 8,9. Genome-wide expression studies suggest that depletion of CDK12 abrogates the expression of several HR genes relatively specifically, thereby blunting HR repair 3-7,10,11. This observation suggests that the mutational status of CDK12 may predict sensitivity to targeted treatments against BRCAness, such as PARP1 inhibitors, and that CDK12 inhibitors may induce sensitization of HR-competent tumours to these treatments 6,7,10,11. Despite growing clinical interest, the mechanism by which CDK12 regulates HR genes remains unknown. Here we show that CDK12 globally suppresses intronic polyadenylation events in mouse embryonic stem cells, enabling the production of full-length gene products. Many HR genes harbour more intronic polyadenylation sites than other expressed genes, and these sites are particularly sensitive to loss of CDK12. The cumulative effect of these sites accounts for the enhanced sensitivity of HR gene expression to CDK12 loss, and we find that this mechanism is conserved in human tumours that contain loss-of-function CDK12 mutations. This work clarifies the function of CDK12 and underscores its potential both as a chemotherapeutic target and as a tumour biomarker.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0758-y

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927

Show all 51 references

Sorted by citations

PARP and PARG inhibitors in cancer treatmentPreprint
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 693
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 665
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352
Context-specific regulation and function of mRNA alternative polyadenylation
Mitschka, S., & Mayr, C. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00507-5 · Cited by 349
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 381
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y.-C., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 297
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation
Krajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281
Alternative mRNA splicing in cancer immunotherapy
Frankiw, L., Baltimore, D., & Li, G. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0195-7 · Cited by 253
Causes and consequences of RNA polymerase II stalling during transcript elongation
González, M. N., Blears, D., & Svejstrup, J. Q. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00308-8 · Cited by 262
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Targeting mRNA processing as an anticancer strategy
Desterro, J. M. P., Bak‐Gordon, P., & Carmo‐Fonseca, M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0042-3 · Cited by 181
Targeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N. P., Teng, M., Gray, N. S., & Johnstone, R. W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 170
CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
Fan, Z., Devlin, J. R., Hogg, S. J., Doyle, M. A., Harrison, P. F., Todorovski, I., Cluse, L. A., Knight, D. A., Sandow, J. J., Gregory, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz5041 · Cited by 164
Transcriptional Control by Premature Termination: A Forgotten Mechanism
Kamieniarz-Gdula, K., & Proudfoot, N. J. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.05.005 · Cited by 169
Discovery and resistance mechanism of a selective CDK12 degrader
Jiang, B., Gao, Y., Che, J., Lu, W., Kaltheuner, I. H., Dries, R., Kalocsay, M., Berberich, M. J., Jiang, J., You, I., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00765-y · Cited by 150
A highly annotated database of genes associated with platinum resistance in cancer
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021) · Oncogene · doi:10.1038/s41388-021-02055-2 · Cited by 150
Knowing when to stop: Transcription termination on protein-coding genes by eukaryotic RNAPII
Rodríguez‐Molina, J. B., West, S., & Passmore, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.021 · Cited by 121
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
Nguyen, B., Mota, J. M., Nandakumar, S., Stopsack, K. H., Weg, E. S., Rathkopf, D. E., Morris, M. J., Scher, H. I., Kantoff, P. W., Gopalan, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.024 · Cited by 122
CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
Manavalan, A. P. C., Pilařová, K., Kluge, M., Bartholomeeusen, K., Rájecký, M., Oppelt, J., Khirsariya, P., Paruch, K., Krejčí, L., Friedel, C. C., et al. (2019) · EMBO Reports · doi:10.15252/embr.201847592 · Cited by 114
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 117
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma
Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut · doi:10.1136/gutjnl-2019-318506 · Cited by 107
Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors
Parua, P. K., & Fisher, R. P. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0563-4 · Cited by 105
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 101
Prostate cancer treatment – China's perspective
Liu, J., Dong, L., Zhu, Y., Dong, B., Sha, J., Zhu, H. H., Pan, J., & Xue, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215927 · Cited by 107
CDK12 globally stimulates RNA polymerase II transcription elongation and carboxyl-terminal domain phosphorylation
Tellier, M., Zaborowska, J., Caizzi, L., Mohammad, E., Velychko, T., Schwalb, B., Vicens, I. F., Blears, D., Nojima, T., Cramer, P., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa514 · Cited by 105
CDK9 keeps RNA polymerase II on track
Egloff, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03878-8 · Cited by 104
Sites of Transcription Initiation Drive mRNA Isoform Selection
Alfonso-Gonzalez, C., Legnini, I., Holec, S., Arrigoni, L., Ozbulut, H. C., Mateos, F., Koppstein, D., Rybak‐Wolf, A., Bönisch, U., Rajewsky, N., et al. (2022) · Cell · doi:10.1016/j.cell.2023.04.012 · Cited by 97
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Yang, J., Chang, Y., Tien, J. C.-Y., Wang, Z., Zhou, Y., Zhang, P., Huang, W., Vo, J. N., Apel, I. J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00384 · Cited by 99
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95
CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma
Ross, N. T., Lohmann, F., Carbonneau, S., Fazal, A., Weihofen, W. A., Gleim, S., Salcius, M., Sigoillot, F. D., Hénault, M., Carl, S. H., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0424-1 · Cited by 90
Cell-type-specific analysis of alternative polyadenylation using single-cell transcriptomics data
Shulman, E. D., & Elkon, R. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz781 · Cited by 93
Termination of Transcription by RNA Polymerase II: BOOM!
Eaton, J. D., & West, S. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.05.008 · Cited by 92
U1 snRNP increases RNA Pol II elongation rate to enable synthesis of long genes
Mimoso, C. A., & Adelman, K. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.002 · Cited by 98
RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics
Pandey, P. R., Young, K. H., Kumar, D., & Jain, N. K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01528-6 · Cited by 89
Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcriptionPreprint
Rimel, J. K., Poss, Z. C., Erickson, B., Maas, Z. L., Ebmeier, C. C., Johnson, J. L., Decker, T.-M., Yaron, T. M., Bradley, M. J., Hamman, K. B., et al. (2020) · Genes & Development · doi:10.1101/gad.341545.120 · Cited by 103
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02105 · Cited by 86
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stabilityPreprint
Choi, S. H., Martinez, T. F., Kim, S., Donaldson, C. J., Shokhirev, M. N., Saghatelian, A., & Jones, K. A. (2019) · Genes & Development · doi:10.1101/gad.322339.118 · Cited by 89
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, J., Jermusyk, A. A., Wu, L., Hoskins, J. W., Collins, I. J., Mocci, E., Zhang, M., Song, L., Chung, C. C., Zhang, T., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz246 · Cited by 79
Characterization of Arabidopsis thaliana Promoter Bidirectionality and Antisense RNAs by Inactivation of Nuclear RNA Decay Pathways
Thieffry, A., Vigh, M. L., Bornholdt, J., Ivanov, M., Brodersen, P., & Sandelin, A. (2020) · The Plant Cell · doi:10.1105/tpc.19.00815 · Cited by 76
Targeting DNA Damage Response in Prostate and Breast Cancer
Wengner, A. M., Scholz, A., & Haendler, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218273 · Cited by 81
CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 76
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma
Giuliani, V., Miller, M. A., Liu, C.-Y., Hartono, S. R., Class, C. A., Bristow, C. A., Suzuki, É., Sanz, L. A., Gao, G., Gay, J. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24798-y · Cited by 74
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Lee, E. K., & Matulonis, U. A. (2020) · Cancers · doi:10.3390/cancers12082054 · Cited by 74
The regulation and function of post-transcriptional RNA splicing
Choquet, K., Patop, I. L., & Churchman, L. S. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00836-z · Cited by 71
CDK12 and PAK2 as novel therapeutic targets for human gastric cancer
Liu, H., Shin, S. H., Chen, H., Liu, T., Li, Z., Hu, Y., Liu, F., Zhang, C., Kim, D. J., Liu, K., et al. (2020) · Theranostics · doi:10.7150/thno.46137 · Cited by 70
Oncogenic CDK13 mutations impede nuclear RNA surveillance
Insco, M. L., Abraham, B. J., Dubbury, S. J., Kaltheuner, I. H., Dust, S., Wu, C., Chen, K. Y., Liu, D., Bellaousov, S., Cox, A. M., et al. (2023) · Science · doi:10.1126/science.abn7625 · Cited by 66
Self-citation
ZC3H4 restricts non-coding transcription in human cells
Estell, C., Davidson, L., Steketee, P. C., Monier, A., & West, S. (2021) · eLife · doi:10.7554/elife.67305 · Cited by 67
Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma
Jiang, B., Jiang, J., Kaltheuner, I. H., Iniguez, A. B., Anand, K., Ferguson, F. M., Ficarro, S. B., Seong, B. K. A., Greifenberg, A. K., Dust, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113481 · Cited by 63
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT
Li, H., Wang, J., Yi, Z., Li, C., Wang, H., Zhang, J., Wang, T., Nan, P., Lin, F., Xu, D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.045 · Cited by 64
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
Tadesse, S., Duckett, D. R., & Monastyrskyi, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0240 · Cited by 58
On the function and relevance of alternative 3′‐ UTRs in gene expression regulation
Pereira‐Castro, I., & Moreira, A. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1653 · Cited by 60
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Wang, Y., Bernhardy, A. J., Nacson, J., Krais, J. J., Tan, Y., Nicolas, É., Radke, M. R., Handorf, E., Llop‐Guevara, A., Balmañà, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13530-6 · Cited by 60
Heat shock induces premature transcript termination and reconfigures the human transcriptome
Cugusi, S., Mitter, R., Kelly, G. P., Walker, J., Han, Z., Pisano, P., Wierer, M., Stewart, A., & Svejstrup, J. Q. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.01.007 · Cited by 62
Phosphoproteome profiling uncovers a key role for CDKs in TNF signaling
Tanzer, M. C., Bludau, I., Stafford, C. A., Hornung, V., & Mann, M. (2021) · Nature Communications · doi:10.1038/s41467-021-26289-6 · Cited by 53
Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Cheng, L., Zhou, S., Zhou, S., Shi, K., Cheng, Y., Cai, M., Ye, K., Lin, L., Zhang, Z., Jia, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0222 · Cited by 54
Multiplexed single-cell characterization of alternative polyadenylation regulators
Kowalski, M. H., Wessels, H., Linder, J., Dalgarno, C., Mascio, I., Choudhary, S., Hartman, A., Hao, Y., Kundaje, A. B., & Satija, R. (2024) · Cell · doi:10.1016/j.cell.2024.06.005 · Cited by 56
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
Cesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02682-5 · Cited by 51
The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma
Houles, T., Boucher, J., Lavoie, G., MacLeod, G., Lin, S., Angers, S., & Roux, P. P. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01754-x · Cited by 49
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
da Costa, A. A. B. A., & Baiocchi, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.016 · Cited by 48
Oncogenic dysregulation of pre‐mRNA processing by protein kinases: challenges and therapeutic opportunities
Naro, C., Bielli, P., & Sette, C. (2021) · FEBS Journal · doi:10.1111/febs.16057 · Cited by 49
Enhancers regulate 3′ end processing activity to control expression of alternative 3′UTR isoforms
Kwon, B., Fansler, M. M., Patel, N. D., Lee, J., Ma, W., & Mayr, C. (2022) · Nature Communications · doi:10.1038/s41467-022-30525-y · Cited by 47
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
Filippone, M. G., Gaglio, D., Bonfanti, R., Tucci, F. A., Ceccacci, E., Pennisi, R., Bonanomi, M., Jodice, G., Tillhon, M., Montani, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30375-8 · Cited by 46
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 45
Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
Constantin, T. A., Greenland, K. K., Varela‐Carver, A., & Bevan, C. L. (2022) · Oncogene · doi:10.1038/s41388-022-02347-1 · Cited by 46
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
Tien, J. C.-Y., Luo, J., Chang, Y., Zhang, Y., Cheng, Y., Wang, X., Yang, J., Mannan, R., Mahapatra, S., Shah, P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101758 · Cited by 45
Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma
Veo, B. L., Danis, E. P., Pierce, A. M., Wang, D., Fosmire, S. P., Sullivan, K. D., Joshi, M., Khanal, S., Dahl, N. A., Karam, S. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109013 · Cited by 42
CDK12: cellular functions and therapeutic potential of versatile player in cancer
Pilařová, K., Herudek, J., & Blažek, D. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa003 · Cited by 43
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Baillie, K. E., & Stirling, P. C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.010 · Cited by 42
Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation
Choi, S. H., Kim, S., & Jones, K. A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0442-9 · Cited by 43
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houlès, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 46
Impact of DNA damage repair alterations on prostate cancer progression and metastasis
Lukashchuk, N., Barnicle, A., Adelman, C. A., Armenia, J., Kang, J., Barrett, J. C., & Harrington, E. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1162644 · Cited by 43
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study
Dong, B., Fan, L., Yang, B., Chen, W., Li, Y., Wu, K., Zhang, F., Dong, H., Cheng, H., Pan, J., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7663 · Cited by 42
Quantifying 3′UTR length from scRNA-seq data reveals changes independent of gene expression
Fansler, M. M., Mitschka, S., & Mayr, C. (2024) · Nature Communications · doi:10.1038/s41467-024-48254-9 · Cited by 52
The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy
Xie, D., Li, G., Zheng, Z., Zhang, X., Wang, S., Jiang, B., Li, X., Wang, X., & Wu, G. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101335 · Cited by 41
Comparative Analysis of Mammal Genomes Unveils Key Genomic Variability for Human Life Span
Farré, X., Molina-Fernández, R., Barteri, F., Timmers, P. R. H. J., Joshi, P. K., Oliva, B., Acosta, S., Esteve‐Altava, B., Navarro, A., & Muntané, G. (2021) · Molecular Biology and Evolution · doi:10.1093/molbev/msab219 · Cited by 38
Cancer-associated dynamics and potential regulators of intronic polyadenylation revealed by IPAFinder using standard RNA-seq dataPreprint
Zhao, Z., Xu, Q., Wei, R., Wang, W., Ding, D., Yang, Y., Yao, J., Zhang, L., Hu, Y., Wei, G., et al. (2021) · Genome Research · doi:10.1101/gr.271627.120 · Cited by 40
CDK12 and Integrator-PP2A complex modulates LEO1 phosphorylation for processive transcription elongation
Qiu, M., Yin, Z., Wang, H., Lei, L., Li, C., Cui, Y., Dai, R., Yang, P., Xiang, Y., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8698 · Cited by 40
Mechanism and consequences of herpes simplex virus 1-mediated regulation of host mRNA alternative polyadenylation
Wang, X., Liu, L., Whisnant, A. W., Hennig, T., Djaković, L., Haque, N., Bach, C., Sandri-Goldin, R. M., Erhard, F., Friedel, C. C., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009263 · Cited by 35
CDK12: a potential therapeutic target in cancer
Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.035 · Cited by 36
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 38
U1 snRNP Telescripting Roles in Transcription and Its MechanismPreprint
Di, C., So, B. R., Cai, Z., Arai, C., Duan, J., & Dreyfuss, G. (2019) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2019.84.040451 · Cited by 34
Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment
Shan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 35
CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1
Panzeri, V., Pieraccioli, M., Cesari, E., de la Grange, P., & Sette, C. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad258 · Cited by 35
Alternative polyadenylation alters protein dosage by switching between intronic and 3′UTR sites
de Prisco, N., Ford, C., Elrod, N. D., Lee, W., Tang, L. C., Huang, K.-L., Lin, A., Ji, P., Jonnakuti, V. S., Boyle, L., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4814 · Cited by 35
Divergence in alternative polyadenylation contributes to gene regulatory differences between humans and chimpanzees
Mittleman, B. E., Pott, S., Warland, S., Barr, K., Cuevas, C., & Gilad, Y. (2021) · eLife · doi:10.7554/elife.62548 · Cited by 30
Elevated pre-mRNA 3′ end processing activity in cancer cells renders vulnerability to inhibition of cleavage and polyadenylation
Cui, Y., Wang, L., Ding, Q., Shin, J., Cassel, J. A., Liu, Q., Salvino, J. M., & Tian, B. (2023) · Nature Communications · doi:10.1038/s41467-023-39793-8 · Cited by 31
CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts
Curti, L., Rohban, S., Bianchi, N., Croci, O., Andronache, A., Barozzi, S., Mattioli, M., Ricci, F., Pastori, E., Sberna, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51229-5 · Cited by 33
From cyclins to CDKIs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation
Mademtzoglou, D., & Relaix, F. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113275 · Cited by 32
Chemical inhibitors of transcription-associated kinases
Clopper, K. C., & Taatjes, D. J. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102186 · Cited by 31
CDK12 regulates co-transcriptional splicing and RNA turnover in human cells
Magnuson, B., Bedi, K., Narayanan, I. V., Bartkowiak, B., Blinkiewicz, H., Paulsen, M. T., Greenleaf, A. L., & Ljungman, M. E. (2022) · iScience · doi:10.1016/j.isci.2022.105030 · Cited by 32
Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer
Shen, P., Ye, K., Xiang, H., Zhang, Z., He, Q., Zhang, X., Cai, M., Chen, J., Sun, Y., Lin, L., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj0123 · Cited by 25
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Chou, J., Robinson, T. M., Egusa, E. A., Lodha, R., Zhang, M., Badura, M. L., Mikayelyan, M., Delavan, H. M., Swinderman, J. T., Wilson, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3785 · Cited by 28
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer
Orhan, E., Velázquez, C., Tabet, I., Fenou, L., Rodier, G., Orsetti, B., Jacot, W., Sardet, C., & Theillet, C. G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216820 · Cited by 25
Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities
Araki, S., Ohori, M., & Yugami, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1152087 · Cited by 30
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader
Zhou, L., Zhou, K., Chang, Y., Yang, J., Fan, B., Su, Y., Li, Z., Mannan, R., Mahapatra, S., Ding, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01596 · Cited by 26
Comprehensive characterization of somatic variants associated with intronic polyadenylation in human cancers
Zhao, Z., Xu, Q., Wei, R., Huang, L., Wang, W., Wei, G., & Ni, T. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab772 · Cited by 27
CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer
Sun, R., Wei, T., Ding, D., Zhang, J., Chen, S., He, H. H., Wang, L., & Huang, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205509119 · Cited by 26
Recent advances in the development of cyclin-dependent kinase 7 inhibitors
Teng, Y., Lu, K., Zhang, Q., Zhao, L., Huang, Y., Ingarra, A. M., Galons, H., Li, T., Cui, S., Yu, P., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111641 · Cited by 24

Authors: Dubbury, S. J., Boutz, P. L., & Sharp, P. A.
Affiliations: Koch Institute for Integrative Cancer Research At MIT (US)
University of Rochester Medicine (US)
Corresponding author: Sharp, Phillip A.
ORCID: Dubbury, Sara J.
Boutz, Paul L.
Sharp, Phillip A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-11-28
Volume: 564
Issue: 7734
Pages: 141-145
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-018-0758-y
PMC: PMC6328294
OpenAlex: W2806593114
Cited by: 318
References: 51
Citations by year: 2026: 48 · 2025: 35 · 2024: 54 · 2023: 36 · 2022: 46 · 2021: 36 · 2020: 39 · 2019: 23
FWCI: 8.80
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051)
National Institutes of Health (GM034277, R01-GM034277)
U.S. Public Health Service (P30-CA14051, R01-GM034277, R01CA133404)
National Cancer Institute (R01CA133404, P01CA042063, CA14051, R01CA226898, P30CA014051, P30-CA-14051)
National Institute of General Medical Sciences (R01GM034277, T32GM007287)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: CDK12, intronic polyadenylation, homologous recombination, DNA repair genes, BRCAness, PARP-1 inhibitors, CDK12 inhibitors, tumour biomarkers, chemosensitization, mouse embryonic stem cells
MeSH terms: Mouse Embryonic Stem Cells, Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Loss of Function Mutation, Animals, DNA Damage, DNA Repair, Humans, Introns, Mice, Inbred C57BL, Mutation, Neoplasms, Phosphorylation, RNA Polymerase II, Serine, Biomarkers, Tumor, Cyclin-Dependent Kinases, Polyadenylation, Mice, Molecular Targeted Therapy, Homologous Recombination, Transcription Elongation, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CDK12 regulates DNA repair genes by suppressing intronic polyadenylation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks